Mark Cuban Cost Plus Drug Co. has added Starjemza, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab), to its portfolio.
The company, co-founded by billionaire entrepreneur Mark Cuban, is offering two strengths of the biosimilar at $360 per syringe, plus a $55 next-day refrigerated shipping cost. The retail price for the biosimilar is $3,632 at other pharmacies, according to Cost Plus Drugs’ website.
Stelara is approved to treat patients 6 years and older with plaque psoriasis or psoriatic arthritis, as well as adults with Crohn’s disease or ulcerative colitis. The brand-name biologic costs approximately $30,000, while the generic is about $7,200, according to GoodRx.
The biosimilar Starjemza, approved in May, has the same indications.
Read three other updates on Cost Plus Drugs here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
